Medications

Farxiga approved to reduce risk for CKD progression

(HealthDay)—Farxiga (dapagliflozin) oral tablets are now approved for adults with chronic kidney disease at risk for disease progression, the U.S. Food and Drug Administration announced Friday.

Medications

Added benefit of linagliptin is not proven

Linagliptin (trade name: Trajenta) has been approved since August 2011 to improve blood glucose control ("glycaemic control") in adults with type 2 diabetes mellitus whose elevated blood glucose levels are inadequately controlled ...

Medications

Six lithium dose predictors for patients with bipolar disorder

Six predictors could help determine the amount of lithium needed to treat patients with bipolar disorder, according to a large study led by researchers at Karolinska Institutet in Sweden. The study, published in the journal ...

Diseases, Conditions, Syndromes

Peptide shows promise for protecting kidneys from nephritis

A synthetic peptide appears to directly disrupt the destructive inflammation that occurs in nephritis, enabling the kidneys to better recover and maintain their important functions, investigators report.

page 11 from 40